One-glance verdict
Not enough data
Fair value unavailable
Not enough cash-flow history to value this one with our method.
Fundamentals snapshot
Tenaya Therapeutics, Inc.
TNYA · NCM · Healthcare · Biotechnology
Current price
$0.57
52-week range
$0.52 - $2.07
Market cap
$126.80M
Balance sheet
Healthy
-34.80x Concerning
Net cash $74.14M. Interest coverage shows how many times profit covers the interest bill.
What stands out
0 Rewards
2 Risks
0 rewards · 2 risks
- Risk Return on equity was -121.9% last year — the company lost money on shareholders' equity.
- Risk Insider ownership is only 0.5% (peer median: 1.2%).
What this company does
Tenaya Therapeutics, Inc.
Tenaya Therapeutics is a company working on new medicines for heart diseases, with a focus on gene therapies like TN-201 and TN-401 that are currently in testing. Their main source of money will eventually come from selling these approved medicines, which matters because if successful, they could offer much-needed treatments for patients with specific inherited heart conditions. They also have a partnership with another company to find new ways to target heart problems.
How the company got here
Tenaya Therapeutics was founded in 2016 by scientists who were experts in heart disease and genetics. They wanted to use new discoveries in these fields to create treatments for heart conditions. The company focused on developing therapies that could fix the root causes of heart disease, rather than just managing symptoms. In 2021, Tenaya Therapeutics became a publicly traded company through an initial public offering (IPO), which is when a private company first sells shares of stock to the public, to raise money for its research and development efforts.
What it actually does
Tenaya Therapeutics is a biotechnology company that focuses on discovering and developing new medicines for heart disease. They work on treatments that aim to fix the underlying genetic or cellular problems that cause heart conditions. Their approach involves using advanced science to create therapies that could potentially cure heart disease, rather than just treating the symptoms.
Gene Therapy
This part of Tenaya's business focuses on using gene therapy to treat heart disease. Gene therapy involves delivering a functional copy of a gene to a patient's cells to correct a genetic defect that causes disease. Tenaya's lead gene therapy candidates, TN-201 and TN-401, are designed to treat specific genetic forms of cardiomyopathy, which is a disease of the heart muscle.
Cellular Regeneration
Tenaya is also exploring cellular regeneration as a way to treat heart disease. This approach aims to repair or replace damaged heart cells to restore the heart's function. While specific product candidates in this area are less detailed in public information, it represents a key platform for the company's broader strategy to address heart conditions at a fundamental level.
Precision Medicine
The precision medicine platform at Tenaya involves developing targeted therapies, often small molecules, that address specific molecular pathways involved in heart disease. This approach uses detailed scientific understanding of diseases to create treatments that are highly specific to the underlying cause. Their candidate TN-301, a small molecule inhibitor, is an example of this platform, targeting heart failure with preserved ejection fraction.
What management is betting on now
Tenaya's management is focused on advancing its most promising drug candidates through clinical trials, particularly its gene therapies TN-201 and TN-401. They are also investing in enhancing their scientific platforms, including gene editing and capsid engineering, to improve their ability to deliver treatments. The company aims to generate data from ongoing studies to support future regulatory approvals and ultimately bring these potentially curative therapies to patients with serious heart conditions.
Price history
How the share price has moved
—
Loading price history…
Earnings history
Last 8 quarters — what happened
Click any quarter to read the call summary and what the numbers say.
FY2024 Q3
$-20.02M
FY2024 Q4
$-18.59M
FY2025 Q1
$-23.50M
FY2025 Q2
$-15.76M
FY2025 Q3
$-15.62M
FY2025 Q4
$-14.01M
FY2026 Q1
$-19.25M
FY2026 Q2
$-3.71M
Revenue
$1.11M
Net income
$-43.39M
Diluted EPS
-0.20
Operating cash flow
$-3.55M
Free cash flow
$-3.71M
Fetching…
Sources
Revenue
$225.00K
Net income
$-19.27M
Diluted EPS
-0.09
Operating cash flow
$-19.23M
Free cash flow
$-19.25M
Fetching…
Sources
Revenue
—
Net income
$-20.18M
Diluted EPS
-0.09
Operating cash flow
$-13.94M
Free cash flow
$-14.01M
Fetching…
Sources
Revenue
—
Net income
$-20.27M
Diluted EPS
-0.12
Operating cash flow
$-15.60M
Free cash flow
$-15.62M
Fetching…
Sources
Revenue
$0.00
Net income
$-23.28M
Diluted EPS
-0.14
Operating cash flow
$-15.61M
Free cash flow
$-15.76M
Fetching…
Sources
Revenue
$0.00
Net income
$-26.86M
Diluted EPS
-0.24
Operating cash flow
$-23.11M
Free cash flow
$-23.50M
Fetching…
Sources
Revenue
—
Net income
$-23.84M
Diluted EPS
-0.27
Operating cash flow
$-18.39M
Free cash flow
$-18.59M
Fetching…
Sources
Revenue
—
Net income
$-25.63M
Diluted EPS
-0.30
Operating cash flow
$-19.84M
Free cash flow
$-20.02M
Fetching…
Sources
Is it cheap or expensive?
Fair value — vs current price $0.57
We couldn't calculate a fair value right now.
Is it drowning in debt?
Healthy
Net cash $74.1M - more cash than debt. Interest coverage -34.8x.
Net debt
$-74.14M
Interest coverage
-34.80x
Tenaya Therapeutics, Inc.'s profit covers its interest bill about 0.0 times over. which is weaker than most peers shown here and 3 peers sit below 1x, which is the danger zone where profit does not fully cover the interest bill.
Healthy
Worse cushion
Baseline
Better cushion
TNYA
BASELINE
Tenaya Therapeutics, Inc.
Total debt $3.95M Interest coverage -34.80x This is the baseline the peer rows are being compared against.
Total debt $15.51M Interest coverage -16.10x Neither company has much profit cushion over interest right now.
Total debt $247.36M Interest coverage -8.77x Neither company has much profit cushion over interest right now.
Total debt $73.41M Interest coverage -15.10x Neither company has much profit cushion over interest right now.
Total debt $26.25B Interest coverage 11.43x This peer still has a real interest-payment cushion, while TNYA does not.
What you should know
The case for and against TNYA
0 Rewards
2 Risks
Rewards
Risks
-
Return on equity was -121.9% last year — the company lost money on shareholders' equity.
-
Insider ownership is only 0.5% (peer median: 1.2%).
The numbers
All the key metrics, grouped by purpose
Tap any ? icon to learn what it means.
Valuation
How expensive the stock looks
P/E (TTM)
—
Forward P/E
-1.44x
P/B
1.82x
P/S
94.98x
EV/EBITDA
-0.70x
PEG ratio
—
Profitability
How much profit each dollar creates
Gross margin
100.0%
Operating margin
-1,882.8%
Net margin
0.0%
ROE
-121.9%
ROA
-47.9%
Health
Liquidity and balance-sheet strength
Debt / equity
0.06x
Current ratio
4.52x
Quick ratio
4.12x
Total debt
$3.95M
Total cash
$78.08M
Growth
How the business has been compounding
Revenue TTM
$1.33M
Revenue 5Y CAGR
—
EPS TTM
-0.53
EPS 5Y CAGR
—
Cash flow
How much cash the business throws off
Operating CF TTM
$-52.33M
Free CF TTM
$-68.88M
FCF margin
-5,159.7%
Dividend
Shareholder payout
Yield
0.0%
Payout ratio
—
Last ex-div date
—